Skip to main content
AIM ImmunoTech Inc. logo

AIM ImmunoTech Inc. — Investor Relations & Filings

Ticker · AIM ISIN · US42366C3016 US Professional, scientific and technical activities
Filings indexed 1,091 across all filing types
Latest filing 2025-03-05 Director's Dealing
Country US United States of America
Listing US AIM

About AIM ImmunoTech Inc.

https://aimimmuno.com/

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various diseases. The company's primary areas of focus include oncology, immune disorders, and viral diseases. Its lead drug candidate is Ampligen® (rintatolimod), a proprietary immuno-modulator with broad-spectrum activity demonstrated in pre-clinical testing. Ampligen® is being evaluated in multiple clinical studies for a range of debilitating and life-threatening conditions.

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing
2025-03-05 English
Director's Dealing 2025
Director's Dealing
2025-03-04 English
Director's Dealing 2025
Director's Dealing
2025-03-04 English
Director's Dealing 2025
Director's Dealing
2025-03-04 English
Director's Dealing 2025
Director's Dealing
2025-03-04 English
Proxy Solicitation & Information Statement 2025
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a Proxy Statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is titled as a Preliminary Proxy Statement for a Special Meeting of Stockholders. The content includes details about the meeting, voting instructions, proposals to be voted on (specifically a reverse stock split), and other proxy-related information. There is no financial data or report content, but rather materials soliciting shareholder votes and providing information about the meeting and proposals. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is substantial (15,000 characters), indicating it is the full proxy statement, not just an announcement. Therefore, the correct classification is PSI with high confidence.
2025-02-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.